Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease

被引：109

作者：

Tapiola, T

Pirttilä, T

Mikkonen, M

Mehta, PD

Alafuzoff, I

Koivisto, K

Soininen, H

机构：

[1] Univ Kuopio, Dept Neurol, FIN-70211 Kuopio, Finland

[2] Kuopio Univ Hosp, Dept Neurosci & Neurol, SF-70210 Kuopio, Finland

[3] Kuopio Univ Hosp, Dept Pathol, SF-70210 Kuopio, Finland

[4] New York State Inst Basic Res Dev Disabil, Staten Isl, NY 10314 USA

来源：

NEUROSCIENCE LETTERS | 2000年 / 280卷 / 02期

基金：

芬兰科学院;

关键词：

Alzheimer's disease; dementia; cerebrospinal fluid; beta-amyloid; tau;

D O I：

10.1016/S0304-3940(00)00767-9

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Earlier studies have shown elevated levels of tau protein and decreased levels of amyloid beta 42 in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD). We investigated the concentrations of A beta 42, A beta 40 and tau in CSF from AD patients on the baseline and after follow-up period of 3 years using ELISA assays. There was a significant decrease of A beta 42 (P < 0.05) and A beta 40 (P < 0.05) levels with time. AD patients with the duration of the disease 2 years or less at baseline had more pronounced decrease of A beta 42 concentrations compared to those with the duration of the disease more than 2 years at baseline (P < 0.05). CSF tau protein concentrations increased in 9/17 but decreased in 8/17 patients. These results suggest that A beta 42 and A beta 40 may be useful in monitoring the long-term progression of AD particularly in the early stages of the disease. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.

引用

收藏

页码：119 / 122

页数：4

相关论文

共 24 条

[1] Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study [J].

Andreasen, N ;

Vanmechelen, E ;

Van de Voorde, A ;

Davidsson, P ;

Hesse, C ;

Tarvonen, S ;

Räihä, I ;

Sourander, L ;

Winblad, B ;

Blennow, K .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) :298-305

[2] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[3] TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE [J].

ARAI, H ;

TERAJIMA, M ;

MIURA, L ;

HIGUCHI, S ;

MURAMATSU, T ;

MACHIDA, N ;

SEIKI, H ;

TAKASE, S ;

CLARK, CM ;

LEE, VMY ;

TROJANOWSKI, JQ ;

SASAKI, H .

ANNALS OF NEUROLOGY, 1995, 38 (04) :649-652

[4] Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up [J].

Blomberg, M ;

Jensen, M ;

Basun, H ;

Lannfelt, L ;

Wahlund, LO .

NEUROSCIENCE LETTERS, 1996, 214 (2-3) :163-166

[5] Variability in annual mini-mental state examination score in patients with probable Alzheimer disease -: A clinical perspective of data from the consortium to establish a registry for Alzheimer's disease [J].

Clark, CM ;

Sheppard, L ;

Fillenbaum, GG ;

Galasko, D ;

Morris, JC ;

Koss, E ;

Mohs, R ;

Heyman, A .

ARCHIVES OF NEUROLOGY, 1999, 56 (07) :857-862

[6] Assessment of CSF levels of tan protein in mildly demented patients with Alzheimer's disease [J].

Galasko, D ;

Clark, C ;

Chang, L ;

Miller, B ;

Green, RC ;

Motter, R ;

Seubert, P .

NEUROLOGY, 1997, 48 (03) :632-635

[7] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].

Galasko, D ;

Chang, L ;

Motter, R ;

Clark, CM ;

Kaye, J ;

Knopman, D ;

Thomas, R ;

Kholodenko, D ;

Schenk, D ;

Lieberburg, I ;

Miller, B ;

Green, R ;

Basherad, R ;

Kertiles, L ;

Boss, MA ;

Seubert, P .

ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945

[8] ALZHEIMER PATHOLOGY OF PATIENTS CARRYING APOLIPOPROTEIN-E EPSILON-4 ALLELE [J].

HEINONEN, O ;

LEHTOVIRTA, M ;

SOININEN, H ;

HELISALMI, S ;

MANNERMAA, A ;

SORVARI, H ;

KOSUNEN, O ;

PALJARVI, L ;

RYYNANEN, M ;

RIEKKINEN, PJ .

NEUROBIOLOGY OF AGING, 1995, 16 (04) :505-513

[9] INCREASED LEVELS OF TAU-PROTEIN IN CEREBROSPINAL-FLUID OF PATIENTS WITH ALZHEIMERS-DISEASE - CORRELATION WITH DEGREE OF COGNITIVE IMPAIRMENT [J].

HOCK, C ;

GOLOMBOWSKI, S ;

NASER, W ;

MULLERSPAHN, F .

ANNALS OF NEUROLOGY, 1995, 37 (03) :414-415

[10] Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: A longitudinal study [J].

Isoe, K ;

Urakami, K ;

Shimomura, T ;

Wakutani, Y ;

Ji, Y ;

Adachi, Y ;

Takahashi, K .

DEMENTIA, 1996, 7 (03) :175-176